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1. Epstein-Barr virus can cause immune thrombocytopenia, particularly in 
children and young adults. 
2. The usual screening test for Epstein-Barr virus infectious 
mononucleosis, the anti-heterophile antibody, can be negative at the 
time of presentation with hematologic complications, so serology is 
necessary for the diagnosis. 
3. Cerebral venous sinus thrombosis main risk factors are prothrombotic 
state (including oral contraceptives) and infection.  Many cases have 
multiple risk factors present. 
CASE PRESENTATION 
TEACHING POINTS 
CONCLUSIONS 
EPSTEIN-BARR VIRUS (EBV) AND 
IMMUNE THROMBOCYTOPENIA (ITP) 
An 18 year old female with no past medical history awoke with  a severe 
generalized headache associated with nausea, vomiting and photophobia. 
Two weeks prior, she had nasal congestion, mild sore throat, and 
productive cough with yellow sputum which resolved but fatigue persisted. 
She was taking oral contraceptives. Physical exam was normal except for 
significant fatigue. Pertinent labs included a normal WBC, H/H, PT/INR 
and aPTT. Platelets were 20,000 platelets/mm3. CT Head demonstrated 
right transverse sinus thrombosis, with empty delta sign. MRI revealed 
extensive right transverse sinus thrombosis with extension into the right 
internal jugular vein. Peripheral smear showed marked thrombocytopenia 
with occasional large and giant forms, some neutrophils with toxic 
granulation, and occasional reactive-appearing lymphocytes. Her LFTs 
were mildly elevated with AST 116, ALT 120 Unit/L. Abdominal ultrasound 
revealed hepatomegaly with mild echogenicity and a normal sized spleen. 
Viral hepatitis screen was negative. Absolute CD4 count was low 
(182/mm3); HIV negative. Hypercoagulable workup negative. ANA 
negative. Anti-heterophile antibody negative. Epstein-Barr antibody to 
early antigen positive. Epstein-Barr viral capsid antigen IgG positive but 
IgM negative. Epstein-Barr antibody to nuclear antigen positive. She was 
diagnosed with Epstein-Barr virus infectious mononucleosis causing 
immune thrombocytopenia, for which she was treated with 
dexamethasone and intravenous immunoglobulin (IVIG). The infection 
plus oral contraceptives likely resulted in the cerebral venous sinus 
thrombosis, for which she was treated with a heparin drip and then 
transitioned to warfarin. Oral contraceptives were discontinued. She 
received Keppra for seizure prophylaxis. On day 2, her platelets dropped 
to 9,000 platelets/mm3, but then rose to normal by day 12. Her low CD4 
count, mildly elevated LFTs, hepatomegaly and severe fatigue were 
attributed to the Epstein-Barr virus. 
This case illustrates a rare presentation of Epstein-Barr virus infection 
causing both immune thrombocytopenia and cerebral venous sinus 
thrombosis at the same time. The oral contraceptive pills likely played a 
contributing role in addition to the Epstein-Barr virus infection in causing 
the cerebral venous sinus thrombosis. 
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Background. Epstein-Barr virus infection has been associated with a 
variety of hematologic abnormalities, including immune thrombocytopenia, 
hemolytic anemia, aplastic anemia, thrombotic thrombocytopenic 
purpura/hemolytic-uremic syndrome, and disseminated intravascular 
coagulation. EBV appears to be a fairly common cause of ITP in children. 
A study in China found EBV infection in 35/108 (32.4%) children 
diagnosed with ITP1. Another study in China studied spleens of patients 
with ITP and controls and found EBV expression in nine (21.4%) with ITP 
compared to none in the control group2. Mild thrombocytopenia (100-
150,000 platelets/mm3) occurs in 25-50% cases of acute EBV infections, 
but severe thrombocytopenia (<20,000 platelets/mm3) is rare; most cases 
occur in children and young adults3,4. 
Etiology. The etiology of thrombocytopenia in EBV is thought to be 
immune-mediated5. In a review of EBV cases with thrombocytopenia, 7/16 
patients (43%) had anti-platelet antibodies5. Historically splenomegaly was 
considered etiologic; however, only half of EBV patients with severe 
thrombocytopenia have splenomegaly, with no correlation between 
thrombocytopenia and splenic size3.  
Diagnosis. Heterophile antibodies may be absent at the time of 
hematologic complications of EBV, so serologic studies should be done to 
get the diagnosis3. 
Treatement and Prognosis. In cases of ITP due to EBV, the 
thrombocytopenia usually resolves spontaneously in days to weeks. 
Treatment may not be needed, but often standard treatment for ITP 
including steroids and immunoglobulins is given.  Chronic 
thrombocytopenia is very rare.  Fatal cases are rare but may occur due to 
cerebral hemorrhage or splenic rupture3. 
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Background. CVST is rare, with the incidence in children at 7 cases per 
million and in adults at 3-4 cases per million, and it is more common in 
women.  
Etiology. The main risk factors are genetic or acquired prothrombotic state 
and infection. Dual or multi-factorial causes have been identified in 44% of 
cases. Oral contraceptives are a well-identified risk factor, as well as 
pregnancy and post-partum. 
Clinical Presentation. Headache is the most common presenting 
symptom (89%); it is usually acute and severe, non-localized, and 
worsened with Valsalva. Presentation can be variable. Some patients get 
focal neurologic signs, like hemiparesis or acute aphasia (left transverse 
sinus). Seizures occur in 40% of patients. Some patients present with 
encephalopathy. Cavernous sinus syndrome is the least common 
presentation, with oculomotor nerve palsies, facial pain, sensory loss in the 
trigeminal nerve distribution, proptosis, and chemosis. 
Treatment. Anticoagulation is recommended, with a goal INR 2-3.  The 
recommended duration varies, from 3 months for a known acute cause, to 
6-12 months for idiopathic cases, to lifelong if the patient has multiple 
prothrombotic factors or antiphospholipid antibody syndrome. Other 
recommendations include aggressive management of intracranial 
hypertension and medication for seizure prophylaxis. There are no 
guidelines for endovascular treatment, which should be reserved for 
severe cases. 
Prognosis. Mortality for CVST is 8-14%, with death usually due to 
intracerebral hemorrhage. Most cases (87%) result in complete recovery, 
with the venous recanalization rate at 3 and 12 months at 85%. The 
recurrence rate is 2.8%6. 
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